INVESTOR UPDATE

Rob Phillips
MPhil(med), PhD(med), FASE, DMU(cardiol)
CEO
07. 2018

Global Growth Strategy Continues

www.uscom.com.au

DISCLAIMER

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

While Uscom (the "Company") has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. Certain information may relate to protected intellectual property rights owned by Uscom.

The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

USCOM

- Australian medical device company (Healthcare sector)
- 3 product streams earning in multiple currencies
- Cardiovascular and pulmonary device specialists
- Devices address 75% of all global mortality
- Sepsis, heart failure, hypertension, asthma and COPD
- $2.5M cash and approaching cash flow break even
- 2 acquisitions in the last 6 years
- 7 devices for regulatory approval FY 2019
- Global operations – Sydney, Beijing, Budapest
- China focus and Invested in expansion of product, manufacturing and operations for FY 2019 in China and the USA

COMPANY ASX:UCM

Uscom

$3.5M Revenue (2017)	$2.5M Cash	100% Free float
$0.21 VWAP 2018 (15-29)	137M Shares	65% Top 20 shareholders

Sydney Based. Global Focus.

For Uscom it is a time of inflection as our clinical and commercial value is increasingly being acknowledged worldwide and we expand our reach in China.

Major Shareholders

Mr Steven Meng 17.34%

Prof Rob Phillips 17.128%

Mr Gary Davey 4.57%

CLINICAL USE

Uscom

235M

people suffer from **asthma**, a common disease among children. More than 3 million people die each year from **COPD**, an estimated 6% of all deaths worldwide.



17.7M

people die every year due to **cardiovascular disease.** By 2030, almost 23.6 million people will die from CVDs, mainly from heart disease and stroke. These are projected to remain the single leading causes of death.

1.13B

people are affected by **hypertension.** Complications of raised blood pressure include stroke, heart failure, peripheral vascular disease, renal impairment and visual impairment.

PRODUCTS

The **USCOM 1A** is a non-invasive advanced hemodynamic monitor that measures cardiovascular function using Doppler Ultrasound to detect abnormalities and guide treatment.

Applications: Heart failure, hypertension, sepsis, pre-eclampsia and fluid management in neonates, children and adults.

The **BP+** measures blood pressure and pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The BP+ Reporter is a results, archiving, analysis and reporting software for use with the BP+.

Applications: hypertension and heart failure in children and adults.

SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi-path ultrasound technology. SpiroSonic devices can be coupled with mobile applications and proprietary software with wireless interfacing for eHealth monitoring.

Applications: Asthma, COPD and OLD in children and adults.

STRATEGY

Uscom is laser focused on growing existing operations to support expanded manufacturing to meet anticipated new revenue from the release of multiple new products across 4 continents.

- Non-invasive cardiovascular and pulmonary monitoring specialists
- Growth focused with organic and incremental global strategies
- Acquisitions of 2 medical device companies
- Expansion of global manufacturing, sales and distribution network
- Uscom China– new China operations regulatory, IP, distribution, and sales
- Deliver 7 new products to revenue in FY2019
- US sales expansion
- New European manufacturing accreditation

Uscom

GROWTH OPPORTUNITY



CFDA	CFDA*	CFDA*
CE	CE	CE
FDA	FDA*	FDA*

* New approvals/sales for FY2019



New BP+, Spiro sales following CFDA and FDA approvals

FY2019 = More products + new regions = increased sales

ACHIEVEMENTS FY2018

Uscom Australia

- New head office with expanded manufacturing capability

Uscom China

- Uscom China established
- Beijing Office established
- Appointment of Ms T. Guo, Director of China Operations
- New IP applications (patents, TM and copyrights)
- Increased marketing and distribution
- Capital consolidation - $3.5M capital raising

Uscom Europe

- New EuroStars Grant for SpiroSonic ($0.33M over 2 years)
- Current EuroStar Grants proceeding (~$1.2M over 3 years)
- Increased manufacturing capacity -Budapest, Hungary

Uscom USA

- Uscom listed on USA GSA – Vendor to US Govt
- US Patent granted for SpiroSonic multipath ultrasound
- US sales/distribution appointments for impending FDA

New Uscom Headquarters
Sydney, Australia

CHINA GROWTH



China is the biggest, and fastest growing market

China has a 20% yoy growth target for medical device spend

Uscom has a China strategy to leverage this growth….



CHINA

Uscom China established

Direct management of China operations

Teresa Guo - Director of China Operations appointed

New China office (Beijing)

Experienced China investor/partner (~20%)

New IP and Patent applications

Expanded USCOM 1A distribution

Expanded distributor support

New China distribution for BP+ and SpiroSonic

7 new products progressing in CFDA approval cycle

Strategic discussions for on going partnerships, specialised distribution and incremental growth

Ms Teresa Guo MSc (Pharma)
Uscom Director of China Operations
Prior – Bayer, China and Sihuan Pharma, China

Uscom

SYDNEY BASED. GLOBALLY FOCUSSED

NEW PRODUCTS

BP+ Reporter

The BP+ Reporter is an archiving analysis, storage and reporting software that's coupled with the BP+. The BP+ Reporter provides 25 measures of BP and 3 separate pulse pressure waves for analysis and provides more BP information than any other technology from a simple 45s measure.

SpiroSonic PRO

Digital ultrasonic spirometer combined with multiparametric physiology measures in a single product.

SpirO3

Proprietary ozone disinfectant device for SpiroSonic spirometers and sleep medicine face masks.

NEW RELEASE

Uscom Advanced Haemodynamics App

The Uscom Advanced Hemodynamics App provides normal values for 26 USCOM 1A derived parameters in adults (range specified from 16 years up), pediatrics (from neonates to 16yr olds), and in pregnancy. English and Chinese versions

Scan the QR code to start using the application.



NEW TECHNOLOGY

Lung Cancer Diagnostic from simple breath test (USECS)

The Uscom Superfrozen Exhaled Breath Condensate (EBC) Collection System (USECS) is a device, designed for easy use in clinical care and scientific research. EBC is a novel method of extracting exosome samples (cells) from a simple breath test for diagnosis of lung cancer, genetic and infectious diseases. This development has been funded by a $2.7M Euro ($3.8M AUD) grant to the consortium of Uscom Limited, the Hungarian Academy of Science, and the Semmelweiss University Medical School. The device is at prototype stage.

MARKETING



Brand Awareness

Strong Message

USCOM LEADERS

"Just yesterday …..We had two very sick premature neonates with septic shock so we didn't switch off our USCOM machine for 24 hours adjusting the doses of inotropes and vasopressors. As a result the babies are feeling much better today and we started withdrawing them from catecholamines.

Thank you from all our team and our little patients!"

Vera Sergeeva, MD, PhD, Dr Med Sci.
Professor and Consultant, NICU, Kursk Regional Perinatal Centre,
PICU, Kursk Regional Child Hospital 2, Kursk, Russia
Fulbright Scholar – Seattle Children's Hospital

MILESTONES

FY 2019

BP+ Reporter released

CFDA (China) for SpiroSonic (FLO, SMART, MOBILE, PRO, SpiroReporter)

CFDA (China) for BP+ and BP+ Reporter

FDA (US) for SpiroSonic (FLO, SMART, MOBILE, PRO, SpiroReporter)

FDA (US) for BP+ and BP+ Reporter

China distribution growth

Manufacturing rationalisation

Growth of European and USA distribution

Revenue growth

HEALTHCARE INVESTMENT

Healthcare +133%; Financials - +36%; Materials +31%; Metals and Mining +31%, Energy - +13%.

Growth, while others languish!

MARKETS

"Dissociation between business and markets creates investor opportunity."

Uscom CEO Rob Phillips





Right sector, right time!

RISKS

Uscom

In the current global environment a diversified high margin medical product offering into multiple key jurisdictions with earnings in key currencies provides a natural hedge against risk. Regardless rapidly growing operations across multiple markets in an increasingly complex and expensive regulatory domain poses unique and considerable risks. Management continually monitor such changes and adjust strategy accordingly.

- Scale up stress as 7 new devices come to market
- China manufacturing and trade policy changes
- Global economy – USA trade war, N Korea, Brexit, South China etc.
- Global health care systems/markets under pressure
- Component availability/manufacturing impacting product supply
- Lumpy revenue – small, rapidly growing and unpredictable
- Regulatory – delays and cost
- Under performance of distributors
- Competitive risks and patent breaches
- Key personnel risks
- Unforeseen ….

OUR FUTURE IS CLEAR

Uscom

CONCLUSION

"Founding our company, acquiring two others, developing 10 products and establishing global sales, marketing and distribution has taken longer and cost more than we thought.

But the opportunity is much greater than we ever anticipated."

Uscom CEO Rob Phillips

INVESTOR UPDATE

Rob Phillips
MPhil(med), PhD(med), FASE, DMU(cardiol)
CEO
07. 2018

Global Growth Strategy Continues

www.uscom.com.au